Answers are grounded in this paper and cite their sources.
The design and total synthesis of dl -6-deoxy-6-(hydroxymethyl)- scyllo -inositol 1:7-cyclic 2,4-trisphosphate ( 4 ), a conformationally restricted cyclic phosphate analogue of the second messenger inositol 1,4,5-trisphosphate [Ins(1,4,5)P 3 ], is described. The protected inosose 2,4,6/3,5-pentahydroxy-3,5-bis- O -( p -methoxybenzyl)-2,4,6- O -methylidynecyclohexanone ( 7 ) was obtained from myo -inositol orthoformate in two steps, and Wittig methylenation and then hydroboration−oxidation using 9-BBN−H/OH - /H 2 O 2 gave the axial hydroxymethyl derivative 9 . A series of protection/deprotection steps provided the diol 13, which was converted into two cyclic phosphate esters 14a and 14b, epimeric at phosphorus, by reaction with (benzyloxy)bis( N, N -diisopropylamino)phosphine /1 H -tetrazole followed by m -CPBA. Two other hydroxyl groups were then exposed and phosphorylated, and total deprotection gave racemic 4 . NMR studies confirmed that in 4 the phosphate group equivalent to the 4-phosphate of Ins(1,4,5)P 3 is held in the positive gauche orientation and that the inositol ring maintains a chair conformation from pH 2 to 12. Investigation of the acid−base properties of 4 using potentiometric and 31 P NMR techniques showed that, over the physiological pH range, 4 behaves as a diprotic acid and that the ionization of the phosphate group equivalent to the 5-phosphate of Ins(1,4,5)P 3 is enhanced. In biological assays, 4 appears to behave as a weak full agonist at the platelet Ins(1,4,5)P 3 receptor, and the possible interpretation of this result is discussed.
No takes yet. Share an insight, caveat, or question.
Riley et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: